Investors & Media

Corporate Profile

Neumentum is dedicated to becoming a leading non-opioid analgesic and neurology specialty pharmaceutical company. More than 100 million Americans suffer from chronic or acute pain, while another 100 million suffer from various neurological disorders, including migraines, low back pain and neck pain.1 Pain medications are often used to help treat these conditions.

Many patients experiencing moderate to severe pain receive prescription opioids, though treatment with opioids comes with inherent risks. Neumentum’s analgesic product candidates have the potential to provide the benefits of safe and effective pain management without the limitations and risks for abuse and misuse that come with opioids.

Neumentum is led by a world-class executive team of biotech and pharmaceutical industry leaders who have extensive pain and neurology experience, from drug development through commercialization. Neumentum has global rights to five novel non-opioid pain products, the most advanced of which are two phase 3-ready injectable products under development for acute postsurgical pain.

Neumentum Confirms Type B Meeting with FDA and Announces New Chief Medical and Scientific Officers

Neumentum, a pharmaceutical company dedicated to transforming the way acute and chronic pain are treated – without opioids – today announced it has confirmed its Type B meeting with the U.S. Food and Drug Administration (FDA). The company also announced its appointment of Robert B. Raffa, Ph.D., as Chief Scientific Officer and Ilona Steigerwald, M.D., as Chief Medical Officer.

PainWeek: New Company Brings New Options for Pain Management

Neumentum announced that it has raised $6 million in a Series A funding round to to advance non-opioid drug candidates for the treatment of postsurgical and acute pain without the opioid-related risks of abuse, misuse and diversion.